Radioactive drug plus immunotherapy for advanced prostate cancer
Treatments studied
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests a combination of a radioactive drug that seeks out prostate cancer cells (Lutetium-177) with an immunotherapy (pembrolizumab). It is for men whose castration-resistant prostate cancer has spread and is no longer controlled by current hormone treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man age 19 or older with advanced prostate cancer that has spread and is no longer responding to hormone therapy.
- Your cancer shows a lot of the PSMA protein on scans (a special PET scan marker).
- You've already tried a newer hormone therapy like abiraterone or enzalutamide, and it stopped working.
- You have not had chemotherapy with docetaxel specifically for this stage of your cancer.
- You have not received immunotherapy (like pembrolizumab) before, and you don't have an active autoimmune disease needing strong immune-suppressing drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an early-stage trial testing a new radioactive treatment (161Tb-PSMA) for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The treatment targets cancer cells using a radioactive metal that may be more effective than older similar treatments.
This trial tests a new drug combination that uses a radioactive molecule to find and treat prostate cancer cells that have spread and are no longer responding to hormone therapy. It may be an option for men with a specific protein called PSMA on their cancer cells.
This trial tests a radioactive medication (177Lu-P17-088) designed to target and treat prostate cancer that has spread to other parts of the body and stopped responding to hormone therapy. The medication is guided to cancer cells using a special imaging scan, potentially offering a new treatment option for men who have already tried other standard therapies.
This trial tests a radioactive treatment (177Lu-PSMA-VG01) that targets a protein called PSMA on prostate cancer cells. It's for men whose cancer has spread and hasn't gotten better with other treatments.
This study tests a radioactive drug called Lu-PSMA-617 for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly to the tumor.
This trial tests a radioactive drug called Lutetium-177 (Lu-177) that targets and kills prostate cancer cells showing a specific marker (PSMA). It's for men with advanced prostate cancer that has spread and stopped responding to hormone therapy, and who have already tried certain chemotherapy or cannot have it.
Hear when a new Metastatic Castration-resistant Prostate Cancer (mCRPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.